Clozapine interacts with the glycine site of the NMDA receptor: Electrophysiological studies of dopamine neurons in the rat ventral tegmental area

Life Sciences

Volumn 83, Issue 5-6, 2008, Pages 170-175

  Schwieler, Lilly ^a   Linderholm, Klas R ^a   Nilsson Todd, Linda K ^a   Erhardt, Sophie ^a   Engberg, Göran ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Electrophysiology; Indomethacin; Kynurenic acid; Parecoxib; Schizophrenia

Indexed keywords

CLOZAPINE; GLYCINE; INDOMETACIN; KYNURENIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PARECOXIB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; IN VIVO STUDY; MALE; NERVE EXCITABILITY; NONHUMAN; RAT; VENTRAL TEGMENTUM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCINE; INDOMETHACIN; KYNURENIC ACID; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; VENTRAL TEGMENTAL AREA;

RATTUS;

EID: 47549106824     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.05.014     Document Type: Article

References (66)

1. Abi-Dargham A., and Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. European Psychiatry 20 1 (2005) 15-27
2. Anden N.E., and Stock G. Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. The Journal of Pharmacy and Pharmacology 25 4 (1973) 346-348
3. Arvanov V.L., and Wang R.Y. Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-d-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. The Journal of Pharmacology and Experimental Therapeutics 289 2 (1999) 1000-1006
4. Arvanov V.L., Liang X., Schwartz J., Grossman S., and Wang R.Y. Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. The Journal of Pharmacology and Experimental Therapeutics 283 1 (1997) 226-234
5. Bartholini G. Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. The Journal of Pharmacy and Pharmacology 28 5 (1976) 429-433
6. Birch P.J., Grossman C.J., and Hayes A.G. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. European Journal of Pharmacology 154 1 (1988) 85-87
7. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., and Carpenter Jr. W.T. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. The American Journal of Psychiatry 151 1 (1994) 20-26
8. Carlsson A., and Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica 20 (1963) 140-144
9. Chen L., and Yang C.R. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. Journal of Neurophysiology 87 5 (2002) 2324-2336
10. Chiodo L.A., and Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 3 8 (1983) 1607-1619
11. Chiodo L.A., and Bunney B.S. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 5 9 (1985) 2539-2544
12. Coyle J.T., and Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 174 1 (2004) 32-38
13. Deutch A.Y., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., and Charney D.S. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophrenia Research 4 2 (1991) 121-156
14. Erhardt S., and Engberg G. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiologica Scandinavica 175 1 (2002) 45-53
15. Erhardt S., Blennow K., Nordin C., Skogh E., Lindström L.H., and Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neuroscience Letters 13 1-2 (2001) 96-98
16. Erhardt S., Oberg H., Mathé J.M., and Engberg G. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20 4 (2001) 353-362
17. Erhardt S., Schwieler L., Emanuelsson C., and Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biological Psychiatry 15 4 (2004) 255-260
18. Erhardt S., Schwieler L., Nilsson L., Linderholm K., and Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiology & Behavior 92 1-2 (2007) 203-209
19. Farde L., Suhara T., Nyberg S., Karlsson P., Nakashima Y., Hietala J., and Halldin C. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 133 4 (1997) 396-404
20. Ganong A.H., and Cotman C.W. Kynurenic acid and quinolinic acid act at N-methyl-d-aspartate receptors in the rat hippocampus. The Journal of Pharmacology and Experimental Therapeutics 236 1 (1986) 293-299
21. Gessa G.L., Devoto P., Diana M., Flore G., Melis M., and Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 22 6 (2000) 642-649
22. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156 2-3 (2001) 117-154
23. Goff D.C., Henderson D.C., Evins A.E., and Amico E. A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia. Biological Psychiatry 45 4 (1999) 512-514
24. Grace A.A., and Bunney B.S. The control of firing pattern in nigral dopamine neurons: single spike firing. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 4 11 (1984) 2866-2876
25. Grace A.A., and Bunney B.S. The control of firing pattern in nigral dopamine neurons: burst firing. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 4 11 (1984) 2877-2890
26. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., and Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 34 10 (1993) 702-712
27. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., and Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 21 19 (2001) 7463-7473
28. Homayoun H., and Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 27 43 (2007) 11496-11500
29. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., and Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 76 5 (2001) 1521-1531
30. Javitt D.C., Duncan L., Balla A., and Sershen H. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Molecular Psychiatry 10 3 (2005) 275-287
31. Jardemark K.E., Ninan I., Liang X., and Wang R.Y. Protein kinase C is involved in clozapine's facilitation of N-methyl-d-aspartate- and electrically evoked responses in pyramidal cells of the medial prefrontal cortex. Neuroscience 118 2 (2003) 501-512
32. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20(3) (1999), Official Publication of the American College of Neuropsychopharmacology 201-225
33. Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45 (1988) 789-796
34. Kapur S., and Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. The American Journal of Psychiatry; 158 3 (2001) 360-369
35. Karoum F., Karson C.N., Bigelow L.B., Lawson W.B., and Wyatt R.J. Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Archives of General Psychiatry 44 7 (1987) 604-607
36. Kessler M., Terramani T., Lynch G., and Baudry M. A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. Journal of Neurochemistry 52 4 (1989) 1319-1328
37. Leysen J.E., Janssen P.M., Schotte A., Luyten W.H., and Megens A.A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 112 1 (1993) 40-54
38. Mansbach R.S., and Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2 4 (1989) 299-308
39. Mansbach R.S., and Geyer M.A. Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology 105 2 (1991) 162-168
40. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 2suppl (1999) 106S-115S
41. Meltzer H.Y., and Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacological Reviews 43 4 (1991) 587-604
42. Miller C.L., Llenos I.C., Dulay J.R., Barillo M.M., Yolken R.H., and Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiology of Disease 15 (2004) 618-629
43. Moghaddam B., and Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. Journal of Neurochemistry 54 (1990) 1755-1760
44. Morris B.J., Cochran S.M., and Pratt J.A. PCP: from pharmacology to modelling schizophrenia. Current Opinion in Pharmacology 5 1 (2005) 101-106
45. Mukherjee J., Christian B.T., Narayanan T.K., Shi B., and Mantil J. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Journal of Neuropsychopharmacology 25 4 (2001) 476-488
46. Murase S., Mathé J.M., Grenhoff J., and Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. Journal of Neural Transmission General Section 91 1 (1993) 13-25
47. Nilsson L.K., Linderholm K.R., Engberg G., Paulson L., Blennow K., Lindstrom L.H., Nordin C., Karanti A., Persson P., and Erhardt S. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophrenia Research 80 2-3 (2005) 315-322
48. Nilsson L.K., Linderholm K.R., and Erhardt. Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons. Journal of Neural Transmission 113 5 (2006) 557-571
49. Nordström A.L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., and Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biological Psychiatry 33 4 (1993) 227-235
50. Nordström A.L., Farde L., and Halldin C. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110 3 (1993) 365-367
51. Parsons C.G., Danysz W., Quack G., Hartmann S., Lorenz B., Wollenburg C., Baran L., Przegalinski E., Kostowski W., Krzascik P., Chizh B., and Headley P.M. Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysiological, biochemical and behavioral characterization. The Journal of Pharmacology and Experimental Therapeutics 283 3 (1997) 1264-1275
52. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th edn (1998), Academic Press, New York
53. Pickar D., Owen R.R., Litman R.E., Konicki E., Gutierrez R., and Rapaport M.H. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Archives of General Psychiatry 49 5 (1992) 345-353
54. Pucak M.L., and Grace A.A. Effects of haloperidol on the activity and membrane physiology of substantia nigra dopamine neurons recorded in vitro. Brain Research 71 (1996) 44-52
55. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 1-2 (1996) 57-73
56. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., and Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biological Psychiatry 50 (2001) 521-530
57. Schwieler L., and Erhardt S. Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid. Neuropsychopharmacology 28 10 (2003) 1770-1777
58. Schwieler L., Engberg G., and Erhardt S. Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse. 52 2 (2004) 114-122
59. Schwieler L., Erhardt S., Nilsson L., Linderholm K., and Engberg G. Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons-possible involvement of endogenous kynurenic acid. Synapse 59 5 (2006) 290-298
60. Seeman P., Corbett R., and Van Tol H.H. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16 (1997) 93-110
61. Sumiyoshi T., Jin D., Jayathilake K., Lee M., and Meltzer H.Y. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. The International Journal of Neuropsychopharmacology 8 3 (2005) 451-455
62. Talley J.J., Bertenshaw S.R., Brown D.L., Carter J.S., Graneto M.J., Kellogg M.S., Koboldt C.M., Yuan J., Zhang Y.Y., and Seibert K. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. Journal of Medicinal Chemistry 43 9 (2000) 1661-1663
63. Tsai G.E., Yang P., Chung L.C., Tsai I.C., Tsai C.W., and Coyle J.T. -serine added to clozapine for the treatment of schizophrenia. The American Journal of Psychiatry 156 11 (1999) 1822-1825
64. Tung C.S., Grenhoff J., and Svensson T.H. Kynurenate blocks the acute effects of haloperidol on midbrain dopamine neurons recorded in vivo. Journal of Neural Transmission. General section 84 (1991) 53-64
65. Wang R.Y. Dopaminergic neurons in the rat ventral tegmental area; I. Identification and characterization. Brain Research Reviews 3 (1981) 123-140
66. White F.J., and Wang R.Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221 (1983) 1054-1057